| Therapeutic intervention in mice deficient for succinate semialdehyde dehydrogenase (gamma-hydroxybutyric aciduria). | |
| | |
MedLine Citation:
|
PMID: 12065715 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Therapeutic intervention for human succinic semialdehyde dehydrogenase (SSADH) deficiency (gamma-hydroxybutyric aciduria) has been limited to vigabatrin (VGB). Pharmacologically, VGB should be highly effective due to 4-aminobutyrate-transaminase (GABA-transaminase) inhibition, lowering succinic semialdehyde and, thereby, gamma-hydroxybutyric acid (GHB) levels. Unfortunately, clinical efficacy has been limited. Because GHB possesses a number of potential receptor interactions, we addressed the hypothesis that antagonism of these interactions in mice with SSADH deficiency could lead to the development of novel treatment strategies for human patients. SSADH-deficient mice have significantly elevated tissue GHB levels, are neurologically impaired, and die within 4 weeks postnatally. In the current report, we compared oral versus intraperitoneal administration of VGB, CGP 35348 [3-aminopropyl(diethoxymethyl)phosphinic acid, a GABA(B) receptor antagonist], and the nonprotein amino acid taurine in rescue of SSADH-deficient mice from early death. In addition, we assessed the efficacy of the specific GHB receptor antagonist NCS-382 (6,7,8,9-tetrahydro-5-[H]benzocycloheptene-5-ol-6-ylideneacetic acid) using i.p. administration. All interventions led to significant lifespan extension (22-61%), with NCS-382 being most effective (50-61% survival). To explore the limited human clinical efficacy of VGB, we measured brain GHB and gamma-aminobutyric acid (GABA) levels in SSADH-deficient mice receiving VGB. Whereas high-dose VGB led to the expected elevation of brain GABA, we found no parallel decrease in GHB levels. Our data indicate that, at a minimum, GHB and GABA(B) receptors are involved in the pathophysiology of SSADH deficiency. We conclude that taurine and NCS-382 may have therapeutic relevance in human SSADH deficiency and that the poor clinical efficacy of VGB in this disease may relate to an inability to decrease brain GHB concentrations. |
| | |
Authors:
|
Maneesh Gupta; Rachel Greven; Erwin E W Jansen; Cornelis Jakobs; Boris M Hogema; Wolfgang Froestl; O Carter Snead; Hilke Bartels; Markus Grompe; K Michael Gibson |
Related Documents
:
|
19007045 - Allometric prediction of the human pharmacokinetic parameters for naveglitazar. 7219665 - Levels of glutamate, aspartate, gaba, and taurine in different regions of the cerebellu... 19476695 - Effects of amino acid neurotransmitters on spontaneous muscular activity of the rumen a... 1964825 - Actions of acetylcholine and gaba on spontaneous contractions of the filariid, dipetalo... 17975905 - Structure-activity and protraction relationship of long-acting glucagon-like peptide-1 ... 19007045 - Allometric prediction of the human pharmacokinetic parameters for naveglitazar. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. |
Journal Detail:
|
Title: The Journal of pharmacology and experimental therapeutics Volume: 302 ISSN: 0022-3565 ISO Abbreviation: J. Pharmacol. Exp. Ther. Publication Date: 2002 Jul |
Date Detail:
|
Created Date: 2002-06-14 Completed Date: 2002-07-12 Revised Date: 2007-11-14 |
Medline Journal Info:
|
Nlm Unique ID: 0376362 Medline TA: J Pharmacol Exp Ther Country: United States |
Other Details:
|
Languages: eng Pagination: 180-7 Citation Subset: IM |
Affiliation:
|
Department of Molecular and Medical Genetics and Pediatrics, Oregon Health & Science University, 2525 SW 3rd Avenue, MP-350, Portland, OR 97201, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aldehyde Oxidoreductases
/
deficiency*,
genetics Animals Benzocycloheptenes / pharmacology Body Weight / drug effects Genotype Injections, Intraperitoneal Longevity / drug effects Mice Mice, Inbred C57BL Mice, Knockout Organophosphorus Compounds / pharmacology Phenotype Sodium Oxybate / metabolism, urine* Succinate-Semialdehyde Dehydrogenase Survival Taste / drug effects Taurine / pharmacology Vigabatrin / pharmacology gamma-Aminobutyric Acid / metabolism |
| Grant Support | |
ID/Acronym/Agency:
|
NS 40270/NS/NINDS NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Benzocycloheptenes; 0/Organophosphorus Compounds; 107-35-7/Taurine; 123690-79-9/CGP 35348; 131733-92-1/NCS 382; 502-85-2/Sodium Oxybate; 56-12-2/gamma-Aminobutyric Acid; 60643-86-9/Vigabatrin; EC 1.2.-/Aldehyde Oxidoreductases; EC 1.2.1.24/Succinate-Semialdehyde Dehydrogenase |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The selective serotonin reuptake inhibitor citalopram induces the storage of serotonin in catecholam...
Next Document: Profound spinal tolerance after repeated exposure to a highly selective mu-opioid peptide agonist: r...